Heron Therapeutics, Inc. (NASDAQ:HRTX) – Stock analysts at Jefferies Group reduced their FY2020 earnings estimates for Heron Therapeutics in a research report issued on Wednesday. Jefferies Group analyst B. Amin now forecasts that the biotechnology company will post earnings of $0.58 per share for the year, down from their prior forecast of $0.71. Jefferies Group has a “Buy” rating and a $26.00 price target on the stock. Jefferies Group also issued estimates for Heron Therapeutics’ FY2021 earnings at $1.85 EPS.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. COPYRIGHT VIOLATION NOTICE: “FY2020 EPS Estimates for Heron Therapeutics, Inc. (NASDAQ:HRTX) Decreased by Jefferies Group” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/fy2020-eps-estimates-for-heron-therapeutics-inc-nasdaqhrtx-decreased-by-jefferies-group/1474044.html.

A number of other equities research analysts have also issued reports on HRTX. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 9th. Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a research report on Friday, May 12th. Cowen and Company set a $40.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 3rd. Aegis reaffirmed a “buy” rating and issued a $33.00 target price on shares of Heron Therapeutics in a research report on Tuesday, July 18th. Finally, ValuEngine raised shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $31.00.

Shares of Heron Therapeutics (NASDAQ HRTX) traded up 2.56% during trading on Friday, hitting $16.00. 766,596 shares of the stock were exchanged. The stock’s 50 day moving average price is $15.36 and its 200-day moving average price is $14.55. Heron Therapeutics has a one year low of $12.21 and a one year high of $22.01.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tang Capital Management LLC boosted its position in Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares during the last quarter. FMR LLC boosted its stake in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after buying an additional 2,158,041 shares in the last quarter. Citadel Advisors LLC boosted its stake in Heron Therapeutics by 529.5% in the first quarter. Citadel Advisors LLC now owns 1,283,679 shares of the biotechnology company’s stock valued at $19,255,000 after buying an additional 1,079,746 shares in the last quarter. Rubric Capital Management LP boosted its stake in Heron Therapeutics by 190.9% in the first quarter. Rubric Capital Management LP now owns 1,600,000 shares of the biotechnology company’s stock valued at $24,000,000 after buying an additional 1,050,000 shares in the last quarter. Finally, Broadfin Capital LLC boosted its stake in Heron Therapeutics by 26.9% in the first quarter. Broadfin Capital LLC now owns 4,947,403 shares of the biotechnology company’s stock valued at $74,211,000 after buying an additional 1,047,816 shares in the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.